Q2 2014 13F Holders as of 30 Jun 2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
16,360,522
-
Shares change
-
+4,552,324
-
Total reported value, excl. options
-
$556,147,916
-
Value change
-
+$154,810,773
-
Number of buys
-
74
-
Number of sells
-
-20
-
Price
-
$34
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2014
101 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2014.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,360,522 shares
of 104,661,494 outstanding shares and own 15.63% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), JENNISON ASSOCIATES LLC (1,121,134 shares), FMR LLC (1,003,700 shares), JPMORGAN CHASE & CO (675,598 shares), Camber Capital Management LLC (630,000 shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (589,000 shares), Polar Capital LLP (577,042 shares), GOLDMAN SACHS GROUP INC (439,702 shares), Arrowpoint Asset Management, LLC (433,457 shares), and WADDELL & REED FINANCIAL INC (380,676 shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.